During disease progression, a variety of immunologic abnormalities are observed regarding cell-mediated immunity in SS patients [2–3], with decreased production of interferon (IFN)-γ (Th1 cytokine), and down-regulated expression of Th1-specific genes, such as TBX21 (T-bet), NKG7, and SCYA5 (RANTES) [2, 4]. The gene discussed is TBX21; the disease is synovial sarcoma.